Almirall updates its oncology pipeline strategy, shares in focus among European pharma peers
Published on 06/23/2026 at 17:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 17:40.
Almirall (ES0157097017) remains positioned as a Spanish specialty pharma player with a focus on dermatology and immunology from its Barcelona base. The stock trades on the Bolsa de Madrid alongside larger European pharma peers such as Sanofi and Bayer, making its strategic focus a key differentiator for investors.
How Almirall positions its pipeline
Almirall concentrates its research and development on medical dermatology, including chronic inflammatory skin diseases such as psoriasis and atopic dermatitis, as well as autoimmune-related indications.
The company typically allocates a mid-teens percentage of its annual revenue to R&D spending, reflecting a strategy that emphasizes organic pipeline development alongside selective in-licensing deals with other biotech and pharmaceutical partners.
Tuesday focus on strategy and peers
Within the broader European pharmaceuticals universe that includes Novartis, Sanofi and Bayer, Almirall is viewed as a mid cap specialist whose fortunes are closely tied to the commercial performance of a concentrated set of key prescription brands in dermatology.
Its listing on the Bolsa de Madrid means the shares are part of the Spanish equity landscape, often compared with other Iberian healthcare names when analysts discuss sector allocation and defensive characteristics during periods of market volatility.
Background and price data on Almirall
Charts, key figures and additional news provide further context for how the Almirall shares trade on the Spanish market.
What the company sells
Almirall generates most of its revenue from prescription dermatology medicines, including treatments for psoriasis, eczema and acne, complemented by a smaller portfolio of respiratory and gastroenterology drugs that provide geographic diversification across Europe and other markets.
Where the stock trades today
The Almirall shares (ES0157097017) last traded on the Bolsa de Madrid at 10.00 euros as of 2026-06-23, 17:30.
Key data on the Almirall shares
- Company: Almirall S.A.
- ISIN: ES0157097017
- WKN: A0CFS0
- Ticker: ALM
- Trading venue: Bolsa de Madrid
- Price (as of 2026-06-23, 17:30): 10.00 EUR
- Market cap: 1.80 billion EUR (as of 2026-06-23)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: IBEX Medium Cap
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
